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ABSTRACT 29 
Background 30 
The 8th edition of the American Joint Committee on Cancer (AJCC) staging system (2018) for 31 
breast cancer (BC) introduced the prognostic stage. Moreover, multigene assessment has been 32 
indicated to tailor staging in T1/T2/N0, ER-positive/HER2-negative BC. However, many National 33 
Health Systems do not provide reimbursement for routine testing. The aim of this study was to 34 
assess whether Ki67 proliferation index is prognostically relevant for patients candidate for 35 
molecular testing.  36 
Methods 37 
A retrospective series of 686 ER+/HER2- BC were reclassified using AJCC 2018, and in the group 38 
of 521 patients for which AJCC 2018 recommends molecular evaluation, we assessed the 39 
prognostic efficacy of a prognostic stage enriched by Ki67 (Ki67-PS), considering Ki67<20% an 40 
alternative to  Recurrence Score<11 provided by Oncotype DX.  41 
Results  42 
We found that a group of BCs (35.6%, 58/163) assigned to IB by prognostic score, were 43 
downstaged to IA with Ki67-PS. The outcome of these 58 cases overlapped with that of lesions 44 
classified as stage IA using prognostic stage, showing a significantly better prognosis compared to 45 
IB tumors (HR = 2.79, p = 0.003).  46 
Conclusions  47 
These data suggest that Ki67 may be a reliable marker to enrich the 2018 AJCC prognostic score in 48 
BC patients candidate for genomic profiling. 49 
  50 
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Background 51 
Breast cancer (BC) is the most common cancer in women. The clinical approach to this 52 
disease varied over the years from radical surgery and aggressive oncological therapy, to the 53 
minimal patient-tailored effective treatment.1,2 54 
Recently, several studies demonstrated that the biological phenotype of the tumor may be a 55 
superior prognostic variable than lymph node staging.3 In particular, Mittendorf et al. described that 56 
among T1 BC patients, estrogen receptor (ER) status and histological grade are better predictors of 57 
survival than presence of small-volume nodal metastases.  58 
Accordingly, the 8th edition of the American Joint Committee on Cancer (AJCC) staging 59 
system, published in 2018, proposed the use of a dual approach based on the traditional anatomic 60 
stage (AS) (i.e. tumor size, lymph node status), which remains unchanged from the 7th AJCC 61 
edition and the novel prognostic stage (PS). This latter takes into account biological information, 62 
such as ER, Progesterone Receptor (PR), HER2 status and histological grade and integrates them 63 
with AS.  64 
To optimize patient care and in particular to allow appropriate treatment de-escalation, 65 
AJCC 2018 recommends molecular profiling in T1/T2 tumors without lymph nodes metastases and 66 
ER-positive/HER2-negative status. Specifically, four tools have been recommended: Oncotype 67 
DX® (level of evidence, I), Mammaprint®, Endopredict® and Breast Cancer Index® (level of 68 
evidence, II). In particular, the AJCC suggested that independently from anatomic stage, ER-69 
positive/HER2-negative tumor should be reclassified as stage IA in case of recurrence score (RS) 70 
<11 by Oncotype DX®.  71 
To date, in many European countries, including Italy, none of these molecular tests is 72 
reimbursed by the National Health System hampering the prompt translation of AJCC 2018 73 
recommendations into the routine clinical practice. In addition, even if approved, these tests could 74 
hamper the budget sustainability of pathology laboratories.   75 
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The proliferation index, assessed using Ki67, is considered an important prognostic 76 
biomarker in BC.4 Ki67 is typically useful in ER-positive/HER2-negative BC, to discriminate, 77 
together with PR, luminal A from luminal B cases, as recommended by St. Gallen guidelines.5 78 
Determination of Ki67 by immunohistochemistry (IHC) is routinely used to integrate the histology 79 
report and to add prognostic information, despite some criticism regarding its reproducibility6 and 80 
different cut off values proposed in literature.5,7,8  81 
Since most of the genes assessed by the previously listed molecular assays are related to cell 82 
proliferation, we hypothesized that a proliferative marker like Ki67 could partly substitute 83 
information obtained by genomic profiling. 84 
The aim of the present study was to evaluate the efficacy of a Ki67-integrated AJCC 2018 85 
prognostic stage (Ki67-PS) for prognostic assessment of patients candidate for molecular assays. In 86 
particular, we firstly reclassified a retrospective series of ER+/HER2- BC using both AJCC 87 
anatomic and prognostic stages. Then, in the subgroup of patients candidate for multigene panel 88 
evaluation according to AJCC, we tested the prognostic efficacy and reliability of a Ki67-integrated 89 
PS (Ki67-PS).  90 
 91 
Methods 92 
Case series 93 
We retrospectively evaluated 686 ER+/HER2– BC patients who underwent conservative surgery at 94 
the Breast Unit of “Città della Salute e della Scienza” University Hospital (Turin, Italy) from April 95 
1998 to December 2012. Data concerning tumor diameter, lymph node involvement, tumor grade, 96 
histological type, ER, PR, HER2, and Ki67 expression levels were obtained from the pathological 97 
reports. In addition, type of therapy and follow up status were collected from clinical reports. All 98 
the cases were anonymously recorded into a dedicated database, and data were accessed 99 
anonymously. The study was conducted in accordance with The Code of Ethics of the World 100 
Medical Association (Declaration of Helsinki) and within the guidelines and regulations defined by 101 
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the Research Ethics Committee for human Biospecimen Utilization (Department of Medical 102 
Sciences – ChBU) of the University of Turin. Considering the retrospective nature of this research 103 
protocol, which involved only already existing medical data that were previously anonymized with 104 
no impact on patient care, no specific written informed consent was required by the Committee. 105 
 106 
Immunohistochemistry 107 
Tissue sections were routinely immunostained using an automated slide processing platform 108 
(Ventana BenchMark AutoStainer, Ventana Medical Systems, Tucson, AZ, USA) with the 109 
following primary antibodies: prediluted anti-ER rabbit monoclonal antibody (SP1, Ventana 110 
Medical Systems); prediluted anti-PgR rabbit monoclonal antibody (1E2, Ventana Medical 111 
Systems) and anti-Ki67 mouse monoclonal antibody (MIB1, diluted 1:50, Dako). Evaluation of 112 
HER2 expression was performed by an anti-HER2 polyclonal antibody (A0485, diluted 1:800, 113 
Dako). Fluorescence in situ hybridization (FISH) was performed to define HER2 status in IHC 114 
equivocal cases (score 2+).9 Positive and negative controls were included for each 115 
immunohistochemical run.  116 
 117 
Pathological evaluation 118 
Tumor size was dichotomized at 15 mm, as suggested by previous studies.10,11 119 
Cut-off for ER and PR positivity was determined at <1%, according to the Consensus of St. Gallen 120 
201112 HER2 was evaluated as recommended by the American Society of Clinical Oncology 121 
(ASCO)/College of American Pathologists (CAP).13 Ki67 proliferation index was assessed on 122 
surgical specimens and a minimum of 1000 cells were evaluated.4 The surrogate of molecular 123 
subtypes obtained from ER, PR and HER2 IHC expression is summarized in Supplementary Table 124 
1. Luminal subtypes were defined according to St. Gallen proposal5 using a Ki67 cut-off value of 125 
20% in line with previously published studies.7,14  126 
 127 
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Anatomic and prognostic staging 128 
All cases (n=686) were firstly staged using anatomic and prognostic stages, then BC in which 129 
further molecular testing (T1/T2, N0, M0) would be recommended according to AJCC 2018 were 130 
selected (n=521).15 We hypothesized that the expression of Ki67 may provide prognostic 131 
information related to those obtained by Oncotype DX. Thus, in analogy to Oncotype DX® RS 132 
<11, we selected a value of Ki67 <20% to identify tumors staged IIA and IB which could be 133 
reclassified as IA. In case of Ki67 values >20%, as for RS >11 the PS was not modified.  134 
 135 
Statistical analysis 136 
Categorical data were described as counts and percentages. Disease Free Interval (DFI) was 137 
determined from the date of diagnosis to the date of first recurrence (either locoregional recurrence 138 
or distant metastasis) or, if no recurrence occurred, analysis was censored at time of last follow up. 139 
DFI was estimated with the Kaplan–Meier analysis. The Cox model was used to assess the 140 
prognostic value of a series of patient and tumor characteristics. Hazard ratios (HRs) and 95% 141 
confidence intervals (CIs) were also calculated. The proportional hazard assumption (Schoenfeld 142 
residuals) was always satisfied. The performance of the AJCC 2018 was informally compared 143 
through the Harrell C or the Somer D discrimination statistics in which the higher value was 144 
representative of better system performance. The Akaike information criterion was also computed, a 145 
lower value indicating the better performance of the model. Data were analyzed with Stata (version 146 
15; Stata Corporation, College Station, TX, US). Concordance among different classification 147 
systems were performed using K Cohen. A two-sided P value of less than .05 was considered 148 
statistically significant. All statistical tests were two-sided. 149 
 150 
Results 151 
Clinico-pathological characteristics  152 
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Clinical and pathological information of 686 patients are reported in Supplementary Table 2. 153 
Briefly, 59.5% of the tumors had a diameter <15 mm and 85% were classified as pT1; of these 154 
42.1% were well differentiated (G1) and 11.4% were poorly differentiated (G3). Lymph nodes 155 
resulted free of metastases in 76.1% of cases. The proliferation rate was low (Ki67 <20%) in 74.1% 156 
of cases. Most of tumors expressed PR and 59.3% were classified as Luminal A. All patients were 157 
treated by conservative surgery followed by radiotherapy. Hormonal therapy was administrated to 158 
95.2% of patients, while 23% received chemotherapy. Distant or local relapse was observed in 58 159 
patients (8.4%) and 21 died of BC (3.1%). 160 
 161 
Classification using AJCC 2018  162 
Patients were staged according to the AJCC 2018 anatomic staging (Fig. 1 - AS). According to this 163 
system, 468 (68.2%), 28 (4.1%), 132 (19.2%) and 39 (5.7%) of tumors were staged as IA, IB, IIA 164 
and IIB respectively, whereas 19 (2.7%) were in stage III (Supplementary Table 3). 165 
Then, we re-staged the tumors using AJCC 2018 prognostic stage (Fig. 1 - PS). Applying this 166 
staging system, the majority of tumors were still classified as IA (63.7%); however, the prognostic 167 
stage reassigned to IA and IB stage the majority of patients previously classified as IB or IIA by 168 
anatomic stage (Supplementary Table 3). 169 
Conversely, 57 cases changed from IA by anatomic stage to IB (51) and IIA (6) according to 170 
prognostic stage. Only 15 out of 39 cases staged as IIB by anatomic stage were confirmed by 171 
prognostic stage, while 14 cases were upstaged into IIIA, 2 were assigned to IIIB and 8 were down 172 
staged to IB (Supplementary Table 3). 173 
Supplementary Table 4 summarized the results obtained by anatomic and prognostic stages, 174 
grouping stage I-II-III patients. Using the new prognostic classification proposed by AJCC the 175 
majority of patients of our series were shifted in stage I [K=0.38, IC95% (0.33-0.41)]. In particular, 176 
using the anatomic stage 5.6% of cases were stage IB, the rate increased to 27.2% using the 177 
prognostic stage. 178 
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 179 
Ki67-integrated Prognostic Stage (Ki67-PS)  180 
We selected 521 patients with BC staged as T1/T2N0M0 that were potential candidates for 181 
molecular assessment following AJCC 2018. Differences between AJCC 2018 anatomic and 182 
prognostic staging are summarized in Supplementary Table 5. In this subgroup, Ki67 proliferation 183 
index was used to integrate the prognostic stage with additional information regarding biological 184 
aggressiveness (Ki67-PS) (Fig. 1 - Ki67-PS).  185 
Clinical and pathological information of this patient group are reported in Table 1. As shown in 186 
Table 2, 411 patients remained assigned to IA stage using both prognostic stage and Ki67-PS, while 187 
58 out of 89 (65,2%) and 3 out of 19 (15,8%) BCs previously classified as IB and IIA respectively 188 
were downstaged to IA, using Ki67-PS. In terms of absolute differences 61/521 (approximately 189 
12%) patients were differently classified.   190 
Table 3 summarizes the results obtained by the three different staging systems, grouping stage I-II-191 
III patients. Prognostic staging (95.9%) and Ki67-PS (96.5%) moved to stage I the majority of BCs. 192 
In general, we observed an overlap between prognostic stage and Ki67-PS, although stage IA 193 
counted more cases (411 vs 472) according to Ki67-PS. 194 
 195 
Outcome analysis according to different staging systems 196 
To understand which staging system could be more accurate to predict the prognosis in ER+ BC 197 
patients, we used Kaplan Meier analysis (Fig. 2 A-C). Only prognostic stage and Ki67-PS clearly 198 
distinguished stage I from stage II and III (Log-rank test p<0.001) (Fig. 2B and 2C, respectively). In 199 
addition, a significant difference of DFI among stages (I-II-III) was observed at univariate analyses 200 
regardless of the staging system used (Table 4). 201 
Based on prognostic stage, DFI was significantly different in stage IA and IB (Log-rank test 202 
p<0.001) (Fig. 2D). In particular, the 58 cases that were downstaged from IB to IA using Ki67-PS 203 
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showed a favorable outcome, similar to those classified as stage IA (p=0.307). (Fig. 2D, Table 4) 204 
and a better prognosis compared to IB lesions (HR=2.79, p=0.003).  205 
 206 
 207 
 208 
 209 
Discussion 210 
In the present study a retrospective series of ER+/HER2- BC with long follow up was 211 
reclassified using both 8th edition AJCC anatomical and prognostic stages. The results obtained 212 
confirm that integration of tumor load (size and presence of node involvement) with tumor type 213 
(grade and prognostic factors) leads to an increased number of patients classified as Stage I, as 214 
previously reported.16,17 Furthermore, in line with other studies,18,19 we found that stage I according 215 
to prognostic stage clearly identifies a group of patients with a more favorable outcome, 216 
distinguishing them from other patients with lesions classified as stage II or III and providing more 217 
accurate prognostic information compared with anatomic stage.  218 
To furtherly improve patient care and avoid unnecessary treatments, AJCC 2018 219 
recommends the use of multigene profiling in the subset of T1/T2-N0, HER2-negative luminal BCs.   220 
However, in many countries, including Italy, the National Health System does not reimburse 221 
these tests, hampering the prompt translation of AJCC 2018 recommendations into the routine 222 
clinical practice.  223 
In absence of molecular assays, Ki67 is to date the only recommended marker, together with 224 
PR, that can help oncologists to differentiate luminal A from luminal B surrogate categories.8  225 
In the present study, we created a prognostic stage integrated with Ki67 (Ki67-PS), 226 
hypothesizing that expression of Ki67 may stratify patients similarly to Oncotype DX®. Actually, 227 
Oncotype DX® is based, among others, on the expression of 5 genes related to proliferation 228 
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(namely MKI67, STK15, Survivin, CCNB1, and MYBL2), and the association between both, RS 229 
and single gene expression, with the Ki67 IHC levels has previously been addressed.20–23 230 
Since use of Oncotype DX® in routine practice requires important financial resources and 231 
its cost-effectiveness has been questioned in the literature,24,25 especially for low risk BC patients, 232 
Ki67-PS can possibly provide additional information with an inferior burden on National Health 233 
System budget. 234 
Several works reported a poor reproducibility of Ki67 assessment due to the use of different 235 
clones (e.g. MIB-1, MM1, NCL-Ki-67p)26 and different pre-analytic procedures, as well as 236 
discordant diagnostic evaluation even in case of dedicated breast pathologists.27 To overcome this 237 
problem, in Italy, breast pathologists and breast pathological labs perform routinely local, regional 238 
and national quality controls, to standardize pre-analytical and analytical assessment of this marker, 239 
according to recommendation by the St Gallen consensus conference.5 In addition, our and other 240 
groups demonstrated that 20% is an optimal cut off of Ki67 to stratify patients with luminal 241 
BCs.14,28,29 Thus, we hypothesized that tumors showing Ki67 <20% may be classified as stage IA, 242 
similarly to those with RS <11.  243 
In the present study, we showed that prognostic score clearly separates stage I tumors from 244 
the others. However, using the integrated Ki67-PS, 61/521 (12%) patients were downstaged from 245 
IB (58 patients) and from IIA (3 patients) to IA with an outcome comparable to those classified as 246 
stage IA defined by prognostic stage in terms of DFI. These data support Ki67 as a possible marker 247 
to identify the subgroup of patients with luminal BC with good prognosis in which treatment de-248 
escalation could be considered.  249 
The present study has some limitations that warrant consideration. Its retrospective nature 250 
limits the collection of follow up data. Due to the small number of patients that died of disease, we 251 
could not perform survival analyses. However, to the best of our knowledge, this is the first study 252 
that reports effective integration of the newly introduced AJCC 2018 prognostic staging system 253 
with Ki67 IHC evaluation. 254 
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In conclusion, our results confirmed that prognostic stage provides better prognostic 255 
information compared to anatomic stage in luminal BC patients. Moreover, the use of Ki67-256 
integrated prognostic stage may be a reliable method to obtain additional prognostic data, enriching 257 
the 2018 AJCC system in BC patients candidate for genomic profiling.  258 
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Figure Legends 373 
Fig. 1: Study flowchart. 374 
 375 
Fig. 2: Disease Free Interval (DFI) of stage I-II-III assessed using AJCC 2018 anatomical stage 376 
(log-rank test p<0.001) (A), prognostic stage (log-rank test p<0.001) (B) and Ki67-PS (log-rank test 377 
p<0.001) (C) (Kaplan Meier analysis). DFI of stage IA and IB assessed using prognostic stage and 378 
of stage IA obtained from downstaging of IB using Ki67-integrated prognostic score (Ki67-PS) 379 
(log-rank test p<0.001) (Kaplan Meier analysis) (D). 380 


Table 1: Clinical and pathological characteristics of patients candidate for molecular profiling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*(PR = Progesterone Receptor) 
 
 N. of patients 
521 
% 
Diameter   
<15 mm 343 65,8
≥15 mm 178 34,2
pT   
1 468 89,8
2 53 10,2
Grade   
1 231 44,3
2 244 46,8
3 46 8,8
Ki67   
<20% 404 77,5
≥20% 117 22,5
PR*   
Negative 33 6,3
Positive 488 93,7
Subtype   
Luminal A 319 61,2
Luminal B 202 38,8
Chemotherapy  
No 468 89,8
Yes 53 10,2
Recurrences   
No 491 94,2
Yes 30 5,8
Table 2: Classification of 521 BC patients according to Prognostic Stage 8th edition AJCC 2018 
and Prognostic Stage modified using Ki67 (Ki67-PS) 
 
  AJCC 2018 Prognostic Stage modified by Ki67 (Ki67-PS)  
  IA IB IIA IIB IIIA Total 
AJCC 2018 
Prognostic Stage 
IA 411 0 0 0 0 411 
IB 58 31 0 0 0 89 
IIA 3 0 16 0 0 19 
IIB 0 0 0 0 0 0 
IIIA 0 0 0 0 2 2 
IIIB 0 0 0 0 0 0 
IIIC 0 0 0 0 0 0 
Total 472 31 16 0 2 521 
 
 
 
Table 3: Classification of 521 BC patients following 8th edition AJCC 2018 (AS, PS and Ki67-PS)  
 
 Stage I Stage II Stage III 
AJCC 2018  
ANATOMIC STAGE 
468 53 0 
IA IB IIA IIB IIIA 
468  
 0 
53 
 0 0 
AJCC 2018  
PROGNOSTIC STAGE 
Stage I Stage II Stage III 
500 19 2 
IA IB IIA IIB IIIA 
411 
 
89 
 
19 
 0 
2 
 
AJCC 2018  
PROGNOSTIC STAGE 
WITH Ki67 
Stage I Stage II Stage III 
503 16 2 
IA IB IIA IIB IIIA 
472 
 
31 
 
16 
 0 
2 
 
 
Table 4:  Univariate analyses on DFI across different staging systems proposed by 8th edition 
AJCC 2018 and using Ki67 integrated PS 
 
System Classification  HR CI p-value 
AJCC 2018 Anatomic Stage (AS) 
Harrel c test 0.6993 AIC 672.6299 
I 1   
II 4.54 2.63-7.82 <0.001 
III 4.62 1.58-13.48 0.005 
AJCC 2018 Prognostic stage (PS) 
Harrel c test 0.6993 AIC 672.6299 
I  1   
II 3.44 1.80-6.57 <0.001 
III 3.87 1.73-8.66 0.005 
AJCC 2018 PS integrated by Ki67 
(Ki67-PS) 
Harrel c test 0.6094 AIC 674.1635 
I  1   
II 3.27 1.67-6.36 0.001 
III 3.79 1.70-8.47 0.001 
AJCC 2018 PS and Ki67-PS 
Harrel c test 0.6265   
IA 1   
IB>IA 1.66 0.62-4.44 0.307 
IB 2.79 1.41-5.53 0.003 
 
 
 
 
 
 
 
 
